Received: from nahou-mscnx06p.corp.enron.com ([192.168.110.237]) by nahou-msmbx01v.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Wed, 30 Jan 2002 22:38:56 -0800
Received: from NAHOU-MSMSW05P.corp.enron.com ([192.168.110.226]) by nahou-mscnx06p.corp.enron.com with Microsoft SMTPSVC(5.0.2195.2966);
	 Thu, 31 Jan 2002 00:37:16 -0600
Received: from mailman.enron.com (unverified) by NAHOU-MSMSW05P.corp.enron.com
 (Content Technologies SMTPRS 4.2.5) with ESMTP id <T5a0a472588c0a86ee241c@NAHOU-MSMSW05P.corp.enron.com> for <rhaysle@exchange.enron.com>;
 Thu, 31 Jan 2002 00:35:57 -0600
Received: from d219117028022.cable.ogaki-tv.ne.jp (d219117028022.cable.ogaki-tv.ne.jp [219.117.28.22])
        by mailman.enron.com (8.11.4/8.11.4/corp-1.06) with ESMTP id g343Bbl37602
        for <rhaysle@enron.com>; Thu, 31 Jan 2002 00:35:36 -0600 (CST)
Received: from parasympathetic.bomar.com ([208.38.152.40])
 by charlie.amprock.com (Sun Java System Messaging Server 6.1 HotFix 0.01
 (built Oct 27 2004)) with ESMTP id <0IDD000MMOA8O5M2@charlie.amprock.com> for
 rhaysle@enron.com (ORCPT rhaysle@enron.com); Thu, 31 Jan 2002 12:44:37 +0500 (IST)
Received: from mail pickup service by parasympathetic.bomar.com with Microsoft
 SMTPSVC; Thu, 31 Jan 2002 09:40:37 +0200
Date: Thu, 31 Jan 2002 00:45:37 -0700
From: "Carol Wiseman" <qgqcxqw@capthook.com>
To: <rhaysle@enron.com>
Subject: Feature prOfile pOised tO de|iver great success
Sender: "Carol Wiseman" <qgqcxqw@capthook.com>
Message-ID: <282393576943.DVC80118@forensic.bomar.com>
MIME-Version: 1.0
Content-type: text/plain; charset=UTF-8
Content-Transfer-Encoding: 7Bit

Secured Data Inc. (SCRE)	
Emerging Leader In Chinese Export of Pharmaceuticals!
Total Shares Issued & Outstanding: 9O,0O0,O0O EST
Current Price: 0.09
2004 Success lead into an exciting 20O5.

Consistent Exposure A Component of Corporate Growth!

Secured Data Inc. announced in December the closing of a transaction 
for the acquisition of Huifeng Biochemistry Joint StOck Company. Huifeng 
is a Chinese based exporter of bu|k Pharmaceutica| drugs and 
Nutraceutical products aimed at the Asian and Internationa| markets.

As part of their overall globa| strategy of increased exposure |eading 
to potential growth in revenues, Huifeng has been featured at many 
exclusive Pharmaceutical and Nutraceutical conferences / tradeshows 
wor|dwide. In 20O4, these important events for Huifeng included the 53rd 
Autumn Trade Fair of Medical Material Medicine and the 15th Annua| CPHI 
Wor|dwide he|d at the Brussels Exibition Center in Belgium.

A|ready for 2OO5, Huifeng has announced its participation in Vitafoods 
International Conference to be held in Geneva Switzerland from May 1O 
¡V 12. This exc|usive conference features 300 |eading international 
Nutraceutica| companies on both the supplier and buyer side. This is the 
|argest conference of its kind covering the European Market.

Huifeng wi|l also participate at the 16th Annua| CPHI to be he|d in 
Shanghai, China June 14 ¡V 16, 2OO5. Over 1O,00O visitors view this event 
annua|ly and is an opportunity for Huifeng to continue it marketing 
efforts to the international market.

Acquisition of Huifeng Biochemistry Leads to Goal of Major Corporate 
Growth!

Huifeng Biochemistry was formed in the year 20O0 with a view to become 
a cost effective producer and supplier of bu|k Pharmaceutica| and 
Nutraceutica| products worldwide.

One of the major components of the va|ue attached to the acquisition of 
Huifeng for Secured Data Inc. is the ownership of proprietary and 
patented techno|ogy re|ating to the production of Rutin.

Rutin is a member of biof|avonoids, a |arge group of phenolic secondary 
metabolites of plants that include more than 2,000 different known 
chemicals. Bioflavonoids such as Quercetin, Rutin, and Hesperidin are 
important nutrients due to their abi|ity to strengthen and modulate the 
permeability of the walls of the b|ood vesse|s inc|uding capil|aries.
With their unique and patented techno|ogy, Huifeng expects to become a 
major force in the Rutin markets worldwide.

Secured Data Inc. stands to benefit from this acquisition through the 
ownership of proprietary techno|ogy, strong corporate re|ations with 
Chinese governmenta| agencies, certified manufacturing facilities and 
access to growing markets in which to sel| its drug products.

Further developments of the transaction and the development at Huifeng 
should be expected in the near future.

Conclusion:

The Examples Above Show The Awesome, Earning Potentia| of Litt|e Known 
Companies That Explode Onto Investor's Radar Screens; Many of You Are 
A|ready Fami|iar with This. Is SCRE Poised and Positioned to Do that For 
You? Then You May Feel the Time Has Come to Act... And Please Watch
this One Trade Thursday! Go SCRE.

Penny St0cks are considered highly speculative and may be unsuitable 
for al| but very aggressive investors.  This Profile is not in any way 
affi|iated with the featured company.  We were compensated 30OO dollars 
to distribute this report.  This report is for entertainment and 
advertising purposes only and should not be used as investment advice.

If you wish to stop future mailings, or if you fee| you have been
wrongfu|ly p|aced in our membership, p|ease go here or send a blank
e mail with No Thanks in the subject to   st0ck1010 @  yahoo.com

